JPMorgan Chase & Co. Has $6.96 Million Stock Holdings in Ingevity Corporation $NGVT

Key Points

• JPMorgan Chase & Co. increased its stake in Ingevity by 66.8% in the third quarter, adding 50,498 shares to hold 126,080 shares valued at $6.96 million (about 0.35% of the company).
• Ingevity recently missed quarterly estimates, reporting $0.58 EPS versus a $0.74 consensus and revenue down 3.2% year-over-year, while setting FY2026 guidance of $4.80–$5.20 per share (sell-side consensus: 4.45).
• The stock has a $2.52 billion market cap, a negative PE (-15.34), high institutional ownership (91.59%), and a consensus analyst rating of Hold with a $80 price target.

JPMorgan Chase & Co. lifted its holdings in shares of Ingevity Corporation (NYSE:NGVT - Free Report) by 66.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 126,080 shares of the company's stock after purchasing an additional 50,498 shares during the period. JPMorgan Chase & Co. owned 0.35% of Ingevity worth $6,958,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Ingevity by 311.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company's stock valued at $23,769,000 after buying an additional 454,579 shares during the period. Simcoe Capital Management LLC raised its stake in Ingevity by 188.8% during the 2nd quarter. Simcoe Capital Management LLC now owns 624,935 shares of the company's stock worth $26,928,000 after buying an additional 408,508 shares during the period. Boston Partners bought a new position in Ingevity in the third quarter worth approximately $14,171,000. Harvey Partners LLC boosted its holdings in Ingevity by 59.6% in the second quarter. Harvey Partners LLC now owns 572,047 shares of the company's stock worth $24,650,000 after acquiring an additional 213,547 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in shares of Ingevity by 217.4% during the third quarter. Marshall Wace LLP now owns 228,201 shares of the company's stock valued at $12,594,000 after acquiring an additional 156,301 shares in the last quarter. Institutional investors and hedge funds own 91.59% of the company's stock.

Ingevity Stock Performance

NGVT stock opened at $71.35 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 1.33 and a debt-to-equity ratio of 39.10. The firm has a market cap of $2.52 billion, a PE ratio of -15.34 and a beta of 1.31. The business has a 50 day moving average of $69.54 and a 200-day moving average of $60.78. Ingevity Corporation has a 12-month low of $28.49 and a 12-month high of $77.46.

Ingevity (NYSE:NGVT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $0.74 by ($0.16). Ingevity had a positive return on equity of 126.25% and a negative net margin of 13.51%.The business had revenue of $255.10 million for the quarter, compared to the consensus estimate of $257.27 million. During the same quarter last year, the business posted $0.95 earnings per share. The business's revenue was down 3.2% compared to the same quarter last year. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. As a group, sell-side analysts expect that Ingevity Corporation will post 4.45 earnings per share for the current year.

Analysts Set New Price Targets

NGVT has been the topic of a number of research reports. Wells Fargo & Company upped their target price on Ingevity from $65.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 27th. BMO Capital Markets reissued an "outperform" rating and issued a $83.00 price target on shares of Ingevity in a research report on Monday, March 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of Ingevity in a research note on Thursday, January 22nd. Zacks Research raised shares of Ingevity to a "hold" rating in a research note on Tuesday, December 16th. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $82.00 price objective on shares of Ingevity in a report on Thursday, February 26th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.